SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022
CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets demonstrating significant pain relief for a majority of patients resulting from 60-day PNS treatment using the SPRINT® PNS System. The presentations include results based on the evaluation of SPRINT in targeting chronic pain in the head, neck, shoulder, and lower back areas. Additional preclinical work being presented at ASRA supports the idea that rapid tissue ingrowth may contribute to a lower infection risk for open-coil leads relative to conventional non-coiled leads.
The abstract titled “Real-world evidence of significant pain relief following 60-day stimulation of occipital nerves for the treatment of chronic pain” features data presented for the first time based on anonymized outcomes of patients who opted in to provide information and were treated for headache pain in the occipital region. Data evaluated by lead author and SPR consultant Dr. Samir Sheth of Sutter Health and other industry leaders showed that of the total 44 patients who opted in to provide information, 82 percent (36/44) of patients were responders at the end of treatment with greater than 50 percent pain relief and/or clinically significant improvement in quality of life. The occipital nerves are a common target for interventional management of conditions such as occipital neuralgia, cervicogenic headache, and other head pain indications and SPRINT is the only implantable PNS system that enables on-label stimulation of the occipital nerve for the treatment of chronic pain.
SPR was awarded a President’s Choice selection for “Durability of relief following 60-day percutaneous PNS of the medial branch nerves for chronic axial low back pain” with lead author and SPR consultant Dr. Christopher Gilmore of Carolinas Pain Institute evaluating sustained pain relief for low back pain patients following completion of SPRINT PNS treatment. One-year post-treatment, 77 percent (48/62) of participants reported clinically meaningful improvement in pain intensity, disability, or pain interference.
Additional abstracts being presented at ASRA include:
“We are excited to join some of the greatest pain management professionals in the world at this important event and share clinical information on the application of the SPRINT PNS Treatment, including new outcome data when utilized in stimulating the occipital and cervical medial branch nerves to treat chronic head and neck pain for patients,” said Josh Boggs, PhD, Chief Scientific Officer at SPR Therapeutics.
About the SPRINT® PNS System
The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.
Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.
For additional information regarding safety and efficacy, visit: SPR Safety Information.
About SPR Therapeutics, Inc.
More information can be found at www.SPRTherapeutics.com.
SPR Contacts: Michelle McDonald Vice President – Marketing [email protected] 844.378.9108 Dave Folkens Public Relations [email protected] 612.978.6547
Cybersecurity Solutions Session
ITEXPO #TECHSUPERSHOW Booth Crawl
IDEA Showcase Startup Pitches & Reception